TCIM
SUPN icon

TIAA CREF Investment Management’s Supernus Pharmaceuticals SUPN Stock Holding History

TIAA CREF Investment Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$6.42M Sell
183,119
-1,968
-1% -$73.2K ﹤0.01% 1288
2018
Q4 		$6.15M Sell
185,087
-1,811
-1% -$77.9K ﹤0.01% 1246
2018
Q3 		$9.41M Sell
186,898
-9,556
-5% -$472K 0.01% 1137
2018
Q2 		$11.8M Buy
196,454
+1,060
+0.5% +$54.9K 0.01% 1055
2018
Q1 		$8.95M Buy
195,394
+76,562
+64% +$3.19M 0.01% 1190
2017
Q4 		$4.74M Sell
118,832
-54,668
-32% -$2.16M ﹤0.01% 1637
2017
Q3 		$6.94M Sell
173,500
-56,005
-24% -$2.42M ﹤0.01% 1412
2017
Q2 		$9.89M Buy
229,505
+4,571
+2% +$163K 0.01% 1143
2017
Q1 		$7.04M Sell
224,934
-7,720
-3% -$207K 0.01% 1361
2016
Q4 		$5.88M Sell
232,654
-9,357
-4% -$209K ﹤0.01% 1493
2016
Q3 		$5.99K Sell
242,011
-9,339
-4% -$211K ﹤0.01% 1477
2016
Q2 		$5.12M Buy
251,350
+60,391
+32% +$1.07M ﹤0.01% 1524
2016
Q1 		$2.91M Buy
190,959
+51,580
+37% +$673K ﹤0.01% 1868
2015
Q4 		$1.87M Sell
139,379
-6,856
-5% -$106K ﹤0.01% 2196
2015
Q3 		$2.05M Buy
146,235
+20,845
+17% +$388K ﹤0.01% 2122
2015
Q2 		$2.13M Buy
125,390
+23,701
+23% +$337K ﹤0.01% 2263
2015
Q1 		$1.23M Hold
101,689
– – ﹤0.01% 2499
2014
Q4 		$844K Sell
101,689
-14,972
-13% -$126K ﹤0.01% 2748
2014
Q3 		$1.01M Sell
116,661
-14,800
-11% -$134K ﹤0.01% 2615
2014
Q2 		$1.44M Buy
131,461
+48,247
+58% +$430K ﹤0.01% 2496
2014
Q1 		$744K Buy
83,214
+23,989
+41% +$221K ﹤0.01% 2800
2013
Q4 		$447K Sell
59,225
-7,140
-11% -$49.9K ﹤0.01% 2992
2013
Q3 		$486K Buy
66,365
+10,829
+19% +$72.7K ﹤0.01% 2946
2013
Q2 		$357K Buy
+55,536
New +$327K ﹤0.01% 3007

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
NPIC
Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

TIAA CREF Investment Management's SUPN Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Supernus Pharmaceuticals (SUPN) stake by 1.1% in Q1 2019, selling an estimated $73.2K and leaving 183,119 shares worth $6.42M. The position accounts for ﹤0.01% of the portfolio, ranked #1288.

TIAA CREF Investment Management first reported a position in SUPN in Q2 2013 and has held it in 24 quarters since. The position peaked at $11.8M in Q2 2018. 289 funds tracked by Wall St. Rank hold SUPN as of Q1 2019.

  • TIAA CREF Investment Management held 183,119 shares of Supernus Pharmaceuticals worth $6.42M as of Q1 2019.
  • TIAA CREF Investment Management sold 1,968 Supernus Pharmaceuticals shares in Q1 2019, an estimated $73.2K.
  • Supernus Pharmaceuticals made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1288 holding.
  • TIAA CREF Investment Management first reported a position in Supernus Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Supernus Pharmaceuticals position peaked at $11.8M in Q2 2018.
  • 289 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.